Proteomic profiling of human embryonic stem cell-derived microvesicles reveals a risk of transfer of proteins of bovine and mouse origin

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

KUBÍKOVÁ Iva KONEČNÁ Hana ŠEDO Ondrej ZDRÁHAL Zbyněk ŘEHULKA Pavel HŘÍBKOVÁ Hana ŘEHULKOVÁ Helena HAMPL Aleš CHMELÍK Josef DVOŘÁK Petr

Year of publication 2009
Type Article in Periodical
Magazine / Source Cytotherapy
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.sciencedirect.com/science/article/pii/S1465324909702804?via%3Dihub
Doi http://dx.doi.org/10.1080/14653240802595531
Field Genetics and molecular biology
Keywords human embryonic stem cell; hESC
Description Microvesicles (MVs) serve as mediators of cell-to-cell communication. However, they may also contain immunogenic domains or infectious particles acquired from xenogenic components of the culture milieu. Therefore, MVs represent a potential risk for the clinical application of cell therapy. We tested the ability of human embryonic stem cells (hESCs) to produce MVs. We found that hESCs are potent producers of MVs and we identified 5 unique protein species that are known to be highly expressed in invasive cancers and that participate in cellular activation, metastasis, and inhibition of apoptosis. Moreover, we found that hESC-derived MVs contain immunogenic agents apolipoprotein and transferrin, as well as mouse retroviral Gag protein. These findings highlight a potential danger of the clinical use of hESCs that have been previously exposed to animal proteins or cells.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info